NOV 18, 2016 07:05 AM PST

Pill Unfurls Into a Star For Truly Extended Drug Release

WRITTEN BY: Xuan Pham
For people who hate to swallow pills or just can’t remember to take their mediation as regularly as they should, scientists may have found a perfect solution. And it’s in the shape of a six-point star.


Currently, people with chronic conditions have to take their medication on a regular basis. And if a patient has multiple conditions, it’s not hard to imagine a brimming pillbox. To help alleviate the need to take the same pills every day, MIT scientists came up with a unique pill that packs enough medicine for extended release in the stomach for days.
 
It may sound simple, but designing such a system is more complex than just making a super potent pill. For one thing, the goal is to have the medicine dissolve slowly over an extended period of time. It would not do the patients any good, and could cause serious complications like an overdose, if a week’s worth of medication was metabolized by the body in a day.
 
The second obstacle of an extended-release pill is keeping the pill inside the stomach for more than a day. This is the current window drug makers have to contend with, as even the most competitive extended release/delayed-release tablets on the market are expelled from the gut in a day’s time.
 
The new contraption, pill that unfurls into a six-pointed star, seemingly overcomes both obstacles, at least in pigs. According to the researchers, the unique multi-pronged shape is what will physically prevent the pill from leaving the stomach. And once safely inside the stomach, the medicine is dissolved one by one with the help of a polymer coating. When the pill is finished, the whole contraption dissolves and is ejected out of the stomach into the small intestine and eventually excreted.
 
While other extended drug release methods are available, such as skin patches and  implantable devices, this is one of the few promising attempts at a truly long-lasting pill. Advantages to the pill would include ease of use and non-invasiveness.
 
Furthermore, the team foresees this technology being especially helpful to patients who suffer silent chronic conditions, like high blood pressure or diabetes. “Some of these diseases do not have symptoms that are perceived daily and in fact are silent to some degree,” said Giovanni Traverso, the study’s lead author. For these patients who may not have constant distress to remind them to take their medication, a long-lasting pill such as this could dramatically increase adherence to prescribed drug regimens.
 

The device is also targeted to less developed countries where medical clinics are far and few in between and medical compliance is already low. In particular, the device is already being tested for treatment against malaria, one of the most pervasive and deadly diseases globally.
 
Additional sources: PopScience
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
JUN 12, 2018
Immunology
JUN 12, 2018
Auto-antibody Detection for Rheumatoid Arthritis Patients
No case of rheumatoid arthritis (RA), an autoimmune disease, is the same. Now, researchers want RA diagnostic approaches to match its pathological diversit...
JUN 20, 2018
Genetics & Genomics
JUN 20, 2018
The Cause of a Rare Neurological Disease is Identified
In a recent study, scientists sequenced the genome to find the mutation behind a disorder that causes blindness and paralysis....
JUN 25, 2018
Microbiology
JUN 25, 2018
Gut Microbes Linked to Development of Liver Disease
The bacteria that live in our gut release compounds that might act as biomarkers, and may be a part of disease development....
JUN 29, 2018
Clinical & Molecular DX
JUN 29, 2018
TRAF7 Mutation Responsible for Mysterious Disorder
A multisystem developmental disorder with specific symptoms shared by seven patients had gone unexplained, but a new genetic sequencing study may provide a...
AUG 22, 2018
Clinical & Molecular DX
AUG 22, 2018
New Clinical Assay Useful For Urothelial Cancer
U.S. Food and Drug Administration (FDA) has now approved a pharmDx assay called ‘Dako PD-L1 IHC 22C3’ by Agilent Technologies Inc. for use in u...
SEP 24, 2018
Genetics & Genomics
SEP 24, 2018
Towards a Blood Test for Drowsy Driving
Driving is an everyday activity for many people around the world, and it comes with serious risks....
Loading Comments...